A Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AB-16B5 in Subjects With an Advanced Solid Malignancy
This is a Phase 1 clinical study to investigate the safety, pharmacokinetics and
pharmacodynamics of AB-16B5 in patients with an advanced solid malignancy. AB-16B5 is a
humanized monoclonal antibody that inhibits the activity of the secreted form of clusterin
(sCLU), a potent inducer of the epithelial-to-mesenchymal transition (EMT). Eligible
subjects will have a disease that has been refractory to prior therapy and is unlikely to
benefit from known therapies.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society